ReviewInternational journal of molecular sciences2013
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer.
Review in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 49 citations in OpenAlex.
- Effect of Essential Oil Components on the Activity of Steroidogenic Cytochrome P450.Biomolecules · 2024Article
- Analyzing the influence of IL18 in regulation of YAP1 in breast oncogenesis using cBioportal.Cancer reports (Hoboken, N.J.) · 2022Article
- New 1,2,3-Triazoles from (R)-Carvone: Synthesis, DFT Mechanistic Study and In Vitro Cytotoxic Evaluation.Molecules (Basel, Switzerland) · 2022Article
- Inhibition of RM-1 prostate carcinoma and eliciting robust immune responses in the mouse model by using VEGF-MGenes and immunity · 2019Article
- Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.Oncotarget · 2017Article
- The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.The Journal of steroid biochemistry and molecular biology · 2016Review
- CYP17 inhibitors in prostate cancer: latest evidence and clinical potential.Therapeutic advances in medical oncology · 2016Review
- Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer.International journal of biological sciences · 2016Review
- Extracting the Benefit of NexrutineCurrent pharmacology reports · 2015Article
- Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.Gene therapy · 2015Article
- CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids · 2015Review
- Article
- Cancer survivors' perspectives and experience on western medicine and traditional Chinese medicine treatment and rehabilitation: a qualitative study.Patient preference and adherence · 2015Article
- Recent advances in bone-targeted therapies of metastatic prostate cancer.Cancer treatment reviews · 2014Review
- CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Nature reviews. Urology · 2014Review
- Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis.American journal of clinical and experimental urology · 2013Review
- Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 2010, six drugs have been approved for the treatment of castration-resistant prostate cancer, i.e., CYP17 inhibitor Abiraterone, androgen receptor antagonist Enzalutamide, cytotoxic agent Cabazitaxel, vaccine Sipuleucel-T, antibody Denosumab against receptor activator of nuclear factor kappa B ligand and radiopharmaceutical Alpharadin. All these drugs demonstrate improvement on overall survival, expect for Denosumab, which increases the bone mineral density of patients under androgen deprivation therapy and prolongs bone-metastasis-free survival. Besides further CYP17 inhibitors (Orteronel, Galeterone, VT-464 and CFG920), androgen receptor antagonists (ARN-509, ODM-201, AZD-3514 and EZN-4176) and vaccine Prostvac, more drug candidates with various mechanisms or new indications of launched drugs are currently under evaluation in different stages of clinical trials, including various kinase inhibitors and platinum complexes. Some novel strategies have also been proposed aimed at further potentiation of antitumor effects or reduction of side effects and complications related to treatments. Under these flourishing circumstances, more investigations should be performed on the optimal combination or the sequence of treatments needed to delay or reverse possible resistance and thus maximize the clinical benefits for the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.